PATIENTS AND METHODS: Patients with mCSPC were prospectively recruited at the Princess Margaret Cancer Centre to the OCTANE trial (NCT02906943). The objective was to assess the feasibility of profiling archival standard diagnostic tumor tissue using next generation sequencing with a custom hybridization capture DNA-based or a targeted DNA/RNA amplicon-based panel. Clinical data were extracted from electronic health records.
RESULTS: Among 39 mCSPC patients enrolled, 21 (54%) had sufficient archival tissue for CGP. Most had high volume (71%) or de novo (71%) mCSPC, with the majority being androgen deprivation therapy (ADT) naïve. In total, 62% of patients had a pathogenic and/or a likely pathogenic variant. Many patients harbored either a pathogenic and/or likely pathogenic variant involving DNA damage repair (DDR, 19%) and cell cycle (24%) pathways; 10% in the AR pathway. After median follow-up of 32.1 months, 18/21 patients progressed, with median time to mCRPC of 14.3 months (95% CI 10.2-21.0). Patients with AR and DDR variants seem to have shorter median time to mCRPC; 10.2 (95% CI 9.50-NR) and 10.3 months (95% CI 6.6-14.3) respectively.
CONCLUSION: In this cohort of highly treatment resistant mCSPC, CGP using archival tumor tissue was feasible for over half of patients, and 62% of patients profiled had a pathogenic and/or a likely pathogenic variant. The presence of de novo variants provides biological basis for evaluating intensification strategies of systemic therapy. This highlights the potential role of routine CGP in biomarker development and clinical trial design in the setting of mCSPC.
MicroAbsract: In this cohort of patients with clinically highly treatment resistant metastatic castrate sensitive prostate cancer, comprehensive genomic profiling was feasible using archival tissue and about one third of patients harbored de novo AR, DDR pathogenic and/or likely pathogenic variant prior to initiating ADT. This is a small cohort but represents patients that were likely not well represented in landmark clinical trials and are important to characterize.
Coralea Kappel, Di Maria Jiang, Bryan Wong, Tong Zhang, Shamini Selvarajah, Evan Warner, Aaron R. Hansen, Nazanin Fallah-Rad, Adrian G. Sacher, Tracy L. Stockley, Philippe L. Bedard, Srikala S. Sridhar
Department of Medicine, McMaster University, Hamilton, Canada; Staff Medical Oncologist, Genitourinary Site, Princess Margaret Cancer Centre, Canada; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
Source: Kappel C, Jiang DM, Wong B et al. "Comprehensive Genomic Profiling of Treatment Resistant Metastatic Castrate Sensitive Prostate Cancer Reveals High Frequency of Potential Therapeutic Targets." Clinical Genitourinary Cancer. 2022. DOI:https://doi.org/10.1016/j.clgc.2022.02.004